BELFAST-based Diaceutics, which provides diagnostic commercialisation to the global pharmaceutical industry, has reported a “very positive” first half of the year, with revenues soaring by a third and its order book growing in line with the board’s ambitious expectations.
BELFAST-based Diaceutics, a leading technology and solutions provider to the pharmaceutical industry, saw its shares jump more than 13 per cent on Monday after it secured a three-year enterprise contract with a top 10 global pharmaceutical company in the US.
BELFAST-based diagnostics technology firm Diaceutics is reflecting on a "transformational year" after reporting that revenues soared 40 per cent to £19.